Drug Trial Radar · NCT07286032
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Apr 16, 2026
Primary completion
Dec 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
Conditions
- Patients With Chemotherapy-Induced Thrombocytopenia
Interventions
Hetrombopag OlamineDrug
For Part A, all participants would receive hetrombopag treatment.
Hetrombopag Olamine; Hetrombopag Olamine PlaceboDrug
For Part B, participants would be randomized to receive hetrombopag treatment or matching placebo, respectively.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Cmax of hetrombopag in non-Asian participants with CIT, around 6 months.Time frame: around 6 months.
- Part A: AUC0-tauof hetrombopag in non-Asian participants with CIT, around 6 months.Time frame: around 6 months.
- Part A: Cmin of hetrombopag in non-Asian participants with CIT, around 6 months.Time frame: around 6 months.
- Part B: A platelet count of ≥100×109/L within 14 days after initiating the investigational product treatment, around 3 years.Time frame: around 3 years.
- Part B: No use of any rescue therapy for thrombocytopenia during the treatment period from the initiation of investigational product treatment until the end of the primary treatment period, around 3 years.Time frame: around 3 years.
- Part B: Complete two consecutive on-study chemotherapy cycles (Cycle 1 and Cycle 2) without thrombocytopenia-induced modification of any myelosuppressive agent, around 3 years.Time frame: around 3 years.
Locations
51 sites in 11 countries. Site status is shown where the registry gives one.
Starling Oncology
Long Beach, California · Not yet recruiting
Cancer and Blood Specialty Clinic
Los Alamitos, California · Recruiting
UCLA
Los Angeles, California · Recruiting
Clermont Oncology Center
Clermont, Florida · Recruiting
Oncology & Hematology Associates of West Broward
Coral Springs, Florida · Recruiting
Starling Oncology / Oncology Institute of Hope & Innovation
Miami, Florida · Not yet recruiting
Mid-Florida Hematology & Oncology Centers, P.A.
Orange City, Florida · Recruiting
Springfield Clinic
Springfield, Illinois · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
Hattiesburg Clinic Hematology/Oncology
Hattiesburg, Mississippi · Not yet recruiting
Cancer Partners of Nebraska
Lincoln, Nebraska · Recruiting
Morristown Medical Center
Morristown, New Jersey · Not yet recruiting
MSK Cancer Center
New York, New York · Not yet recruiting
New York Cancer and Blood Specialists One Oncology
Shirley, New York · Not yet recruiting
ARENSIA Exploratory Medicine at "MBAL Sveta Sofia"
Sofia, Bulgaria · Recruiting
UMHAT "Sv. Ivan Rilski", EAD
Sofia, Bulgaria · Not yet recruiting
Hong Kong United Oncology Centre
Hong Kong, Hong Kong, China · Not yet recruiting
The Chinese University of Hong Kong
Hong Kong, Hong Kong, China · Not yet recruiting
The University of Hong Kong
Hong Kong, Hong Kong, China · Not yet recruiting
Gustave Roussy Cancer Campus
Clémont, France · Recruiting
Centre Hospitalier Lyon Sud
Lyon, France · Not yet recruiting
Groupe Hospitalier Pitie-Salpetriere
Paris, France · Not yet recruiting
Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari
Bari, Italy · Not yet recruiting
Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda)
Milan, Italy · Not yet recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy · Not yet recruiting
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy · Not yet recruiting
Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. ks. B. Markiewicza
Brzozów, Poland · Not yet recruiting
Uniwersytecki Szpital Kliniczny w Poznaniu, Klinika Onkologii
Poznan, Poland · Not yet recruiting
Institutul Oncologic Bucuresti Prof Dr. Al. Trestioreanu with SC Arensia Exploratory Medicine
Bucharest, Romania · Recruiting
Institute of Oncology "Ioan Chiricuta" Cluj-Napoca, Arensia Exploratory Medicine
Cluj-Napoca, Romania · Recruiting
Centrul de Oncologie Sfantul Nectarie Craiova
Craiova, Romania · Not yet recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Not yet recruiting
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Pratia ES Sirius Barcelona
Barcelona, Spain · Recruiting
Hospital Universitario Reina Sofía Córdoba
Córdoba, Spain · Not yet recruiting
Hospital Universitari Arnau de Vilanova
Lleida, Spain · Not yet recruiting
Hospital Universitario HM Madrid Sanchinarro
Madrid, Spain · Not yet recruiting
Hospital Universitario Ramón y Cajal
Madrid, Spain · Not yet recruiting
Pratia ES Hospital Universitario de Torrejon
Madrid, Spain · Recruiting
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.